Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

The effects of genomic germline variant reclassification on clinical cancer care.

Slavin TP, Manjarrez S, Pritchard CC, Gray S, Weitzel JN.

Oncotarget. 2019 Jan 11;10(4):417-423. doi: 10.18632/oncotarget.26501. eCollection 2019 Jan 11.

2.

DNA Damage Repair Alterations are Frequent in Prostatic Adenocarcinomas with Focal Pleomorphic Giant Cell Features.

Lotan TL, Kaur HB, Alharbi AM, Pritchard CC, Epstein JI.

Histopathology. 2019 Jan 12. doi: 10.1111/his.13806. [Epub ahead of print]

PMID:
30636012
3.

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer.

Castro E, Romero-Laorden N, Del Pozo A, Lozano R, Medina A, Puente J, Piulats JM, Lorente D, Saez MI, Morales-Barrera R, Gonzalez-Billalabeitia E, Cendón Y, García-Carbonero I, Borrega P, Mendez Vidal MJ, Montesa A, Nombela P, Fernández-Parra E, Gonzalez Del Alba A, Villa-Guzmán JC, Ibáñez K, Rodriguez-Vida A, Magraner-Pardo L, Perez-Valderrama B, Vallespín E, Gallardo E, Vazquez S, Pritchard CC, Lapunzina P, Olmos D.

J Clin Oncol. 2019 Feb 20;37(6):490-503. doi: 10.1200/JCO.18.00358. Epub 2019 Jan 9.

PMID:
30625039
4.

BRCA2-Associated Prostate Cancer in a Patient With Spinal and Bulbar Muscular Atrophy.

Conteduca V, Sigouros M, Sboner A, Pritchard CC, Beltran H.

JCO Precis Oncol. 2018;2. doi: 10.1200/PO.18.00115. Epub 2018 Jun 29. No abstract available.

5.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Rodrigues DN, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Mendes LST, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Nov 1;128(11):5185. doi: 10.1172/JCI125184. Epub 2018 Nov 1. No abstract available.

6.

Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.

Zafeiriou Z, Bianchini D, Chandler R, Rescigno P, Yuan W, Carreira S, Barrero M, Petremolo A, Miranda S, Riisnaes R, Rodrigues DN, Gurel B, Sumanasuriya S, Paschalis A, Sharp A, Mateo J, Tunariu N, Chinnaiyan AM, Pritchard CC, Kelly K, de Bono JS.

Eur Urol. 2019 Jan;75(1):184-192. doi: 10.1016/j.eururo.2018.09.048. Epub 2018 Oct 16.

7.

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.

Nava Rodrigues D, Rescigno P, Liu D, Yuan W, Carreira S, Lambros MB, Seed G, Mateo J, Riisnaes R, Mullane S, Margolis C, Miao D, Miranda S, Dolling D, Clarke M, Bertan C, Crespo M, Boysen G, Ferreira A, Sharp A, Figueiredo I, Keliher D, Aldubayan S, Burke KP, Sumanasuriya S, Fontes MS, Bianchini D, Zafeiriou Z, Teixeira Mendes LS, Mouw K, Schweizer MT, Pritchard CC, Salipante S, Taplin ME, Beltran H, Rubin MA, Cieslik M, Robinson D, Heath E, Schultz N, Armenia J, Abida W, Scher H, Lord C, D'Andrea A, Sawyers CL, Chinnaiyan AM, Alimonti A, Nelson PS, Drake CG, Van Allen EM, de Bono JS.

J Clin Invest. 2018 Oct 1;128(10):4441-4453. doi: 10.1172/JCI121924. Epub 2018 Sep 4.

8.

Intensive Surveillance with Biannual Dynamic Contrast-Enhanced Magnetic Resonance Imaging Downstages Breast Cancer in BRCA1 Mutation Carriers.

Guindalini RSC, Zheng Y, Abe H, Whitaker K, Yoshimatsu TF, Walsh T, Schacht D, Kulkarni K, Sheth D, Verp MS, Bradbury AR, Churpek J, Obeid E, Mueller J, Khramtsova G, Liu F, Raoul A, Cao H, Romero IL, Hong S, Livingston R, Jaskowiak N, Wang X, Debiasi M, Pritchard CC, King MC, Karczmar G, Newstead GM, Huo D, Olopade OI.

Clin Cancer Res. 2018 Aug 28. doi: 10.1158/1078-0432.CCR-18-0200. [Epub ahead of print]

PMID:
30154229
9.

Characterization of a severe case of PIK3CA-related overgrowth at autopsy by droplet digital polymerase chain reaction and report of PIK3CA sequencing in 22 patients.

Piacitelli AM, Jensen DM, Brandling-Bennett H, Gray MM, Batra M, Gust J, Thaker A, Paschal C, Tsuchiya K, Pritchard CC, Perkins J, Mirzaa GM, Bennett JT.

Am J Med Genet A. 2018 Nov;176(11):2301-2308. doi: 10.1002/ajmg.a.40487. Epub 2018 Jul 31.

PMID:
30063105
10.

A novel disease-causing synonymous exonic mutation in GATA2 affecting RNA splicing.

Wehr C, Grotius K, Casadei S, Bleckmann D, Bode SFN, Frye BC, Seidl M, Gulsuner S, King MC, Percival MB, Pritchard CC, Walsh T, Wu D, Keel S, Salzer U.

Blood. 2018 Sep 13;132(11):1211-1215. doi: 10.1182/blood-2018-03-837336. Epub 2018 Jul 20. No abstract available.

PMID:
30030275
11.

Two-stain immunohistochemical screening for Lynch syndrome in colorectal cancer may fail to detect mismatch repair deficiency.

Pearlman R, Markow M, Knight D, Chen W, Arnold CA, Pritchard CC, Hampel H, Frankel WL.

Mod Pathol. 2018 Dec;31(12):1891-1900. doi: 10.1038/s41379-018-0058-y. Epub 2018 Jul 2.

PMID:
29967423
12.

A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer.

Zhao S, Leonardson A, Geybels MS, McDaniel AS, Yu M, Kolb S, Zong H, Carter K, Siddiqui J, Cheng A, Wright JL, Pritchard CC, Lance R, Troyer D, Fan JB, Ostrander EA, Dai JY, Tomlins SA, Feng Z, Stanford JL.

Prostate. 2018 Jun 28. doi: 10.1002/pros.23667. [Epub ahead of print]

13.

Using Somatic Mutations from Tumors to Classify Variants in Mismatch Repair Genes.

Shirts BH, Konnick EQ, Upham S, Walsh T, Ranola JMO, Jacobson AL, King MC, Pearlman R, Hampel H, Pritchard CC.

Am J Hum Genet. 2018 Jul 5;103(1):19-29. doi: 10.1016/j.ajhg.2018.05.001. Epub 2018 Jun 7.

14.

Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog.

Herman DS, Smith C, Liu C, Vaughn CP, Palaniappan S, Pritchard CC, Shirts BH.

J Mol Diagn. 2018 Jul;20(4):512-521. doi: 10.1016/j.jmoldx.2018.03.010. Epub 2018 May 22.

PMID:
29792936
15.

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.

Boyiadzis MM, Kirkwood JM, Marshall JL, Pritchard CC, Azad NS, Gulley JL.

J Immunother Cancer. 2018 May 14;6(1):35. doi: 10.1186/s40425-018-0342-x.

16.

Histology of colorectal adenocarcinoma with double somatic mismatch-repair mutations is indistinguishable from those caused by Lynch syndrome.

Hemminger JA, Pearlman R, Haraldsdottir S, Knight D, Jonasson JG, Pritchard CC, Hampel H, Frankel WL.

Hum Pathol. 2018 Aug;78:125-130. doi: 10.1016/j.humpath.2018.04.017. Epub 2018 May 1.

PMID:
29723603
17.

Microsatellite instability in prostate cancer by PCR or next-generation sequencing.

Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, Pritchard CC.

J Immunother Cancer. 2018 Apr 17;6(1):29. doi: 10.1186/s40425-018-0341-y.

18.

Corrigendum: Classification and characterization of microsatellite instability across 18 cancer types.

Hause RJ, Pritchard CC, Shendure J, Salipante SJ.

Nat Med. 2018 Apr 10;24(4):525. doi: 10.1038/nm0418-525a.

PMID:
29634692
19.

Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing.

Waalkes A, Smith N, Penewit K, Hempelmann J, Konnick EQ, Hause RJ, Pritchard CC, Salipante SJ.

Clin Chem. 2018 Jun;64(6):950-958. doi: 10.1373/clinchem.2017.285981. Epub 2018 Apr 9.

20.

Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.

Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel WL, Goodfellow PJ, Yilmaz A, Miller K, Bacher J, Jacobson A, Paskett E, Shields PG, Goldberg RM, de la Chapelle A, Shirts BH, Pritchard CC; Ohio Colorectal Cancer Prevention Initiative Study Group.

JAMA Oncol. 2018 Jun 1;4(6):806-813. doi: 10.1001/jamaoncol.2018.0104.

PMID:
29596542
21.

Genetic Mechanisms of Immune Evasion in Colorectal Cancer.

Grasso CS, Giannakis M, Wells DK, Hamada T, Mu XJ, Quist M, Nowak JA, Nishihara R, Qian ZR, Inamura K, Morikawa T, Nosho K, Abril-Rodriguez G, Connolly C, Escuin-Ordinas H, Geybels MS, Grady WM, Hsu L, Hu-Lieskovan S, Huyghe JR, Kim YJ, Krystofinski P, Leiserson MDM, Montoya DJ, Nadel BB, Pellegrini M, Pritchard CC, Puig-Saus C, Quist EH, Raphael BJ, Salipante SJ, Shin DS, Shinbrot E, Shirts B, Shukla S, Stanford JL, Sun W, Tsoi J, Upfill-Brown A, Wheeler DA, Wu CJ, Yu M, Zaidi SH, Zaretsky JM, Gabriel SB, Lander ES, Garraway LA, Hudson TJ, Fuchs CS, Ribas A, Ogino S, Peters U.

Cancer Discov. 2018 Jun;8(6):730-749. doi: 10.1158/2159-8290.CD-17-1327. Epub 2018 Mar 6.

PMID:
29510987
22.

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study.

Mateo J, Cheng HH, Beltran H, Dolling D, Xu W, Pritchard CC, Mossop H, Rescigno P, Perez-Lopez R, Sailer V, Kolinsky M, Balasopoulou A, Bertan C, Nanus DM, Tagawa ST, Thorne H, Montgomery B, Carreira S, Sandhu S, Rubin MA, Nelson PS, de Bono JS.

Eur Urol. 2018 May;73(5):687-693. doi: 10.1016/j.eururo.2018.01.010. Epub 2018 Feb 8.

23.

DNA Repair Pathway Alterations in Metastatic Castration-resistant Prostate Cancer Responders to Radium-223.

Ramos JD, Mostaghel EA, Pritchard CC, Yu EY.

Clin Genitourin Cancer. 2018 Apr;16(2):106-110. doi: 10.1016/j.clgc.2017.11.009. Epub 2017 Dec 6. No abstract available.

PMID:
29287968
24.

Targeted Sequencing of Malignant Supratentorial Pediatric Brain Tumors Demonstrates a High Frequency of Clinically Relevant Mutations.

Cole BL, Pritchard CC, Anderson M, Leary SE.

Pediatr Dev Pathol. 2018 Jul-Aug;21(4):380-388. doi: 10.1177/1093526617743905. Epub 2017 Nov 27.

PMID:
29173061
25.

Corrigendum: Classification and characterization of microsatellite instability across 18 cancer types.

Hause RJ, Pritchard CC, Shendure J, Salipante SJ.

Nat Med. 2017 Oct 6;23(10):1241. doi: 10.1038/nm1017-1241a.

PMID:
28985213
26.

MSH2 Loss in Primary Prostate Cancer.

Guedes LB, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris S, Hicks J, Eisenberger MA, De Marzo AM, Epstein JI, Isaacs WB, Eshleman JR, Pritchard CC, Lotan TL.

Clin Cancer Res. 2017 Nov 15;23(22):6863-6874. doi: 10.1158/1078-0432.CCR-17-0955. Epub 2017 Aug 8.

27.

Prostate Cancer Screening in a New Era of Genetics.

Cheng HH, Pritchard CC, Montgomery B, Lin DW, Nelson PS.

Clin Genitourin Cancer. 2017 Dec;15(6):625-628. doi: 10.1016/j.clgc.2017.05.024. Epub 2017 May 31. Review.

PMID:
28697982
28.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.

Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.

29.

Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies.

Friedlander TW, Pritchard CC, Beltran H.

Am Soc Clin Oncol Educ Book. 2017;37:358-369. doi: 10.14694/EDBK_175510. Review.

30.

Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2.

Haraldsdottir S, Rafnar T, Frankel WL, Einarsdottir S, Sigurdsson A, Hampel H, Snaebjornsson P, Masson G, Weng D, Arngrimsson R, Kehr B, Yilmaz A, Haraldsson S, Sulem P, Stefansson T, Shields PG, Sigurdsson F, Bekaii-Saab T, Moller PH, Steinarsdottir M, Alexiusdottir K, Hitchins M, Pritchard CC, de la Chapelle A, Jonasson JG, Goldberg RM, Stefansson K.

Nat Commun. 2017 May 3;8:14755. doi: 10.1038/ncomms14755.

31.

Features of Patients With Hereditary Mixed Polyposis Syndrome Caused by Duplication of GREM1 and Implications for Screening and Surveillance.

Lieberman S, Walsh T, Schechter M, Adar T, Goldin E, Beeri R, Sharon N, Baris H, Ben Avi L, Half E, Lerer I, Shirts BH, Pritchard CC, Tomlinson I, King MC, Levy-Lahad E, Peretz T, Goldberg Y.

Gastroenterology. 2017 Jun;152(8):1876-1880.e1. doi: 10.1053/j.gastro.2017.02.014. Epub 2017 Feb 24.

PMID:
28242209
32.

Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.

Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Liyanarachchi S, Kalady M, Heald B, Greenwood C, Paquette I, Prues M, Draper DJ, Lindeman C, Kuebler JP, Reynolds K, Brell JM, Shaper AA, Mahesh S, Buie N, Weeman K, Shine K, Haut M, Edwards J, Bastola S, Wickham K, Khanduja KS, Zacks R, Pritchard CC, Shirts BH, Jacobson A, Allen B, de la Chapelle A, Hampel H; Ohio Colorectal Cancer Prevention Initiative Study Group.

JAMA Oncol. 2017 Apr 1;3(4):464-471. doi: 10.1001/jamaoncol.2016.5194.

33.

DNA-Repair Gene Mutations in Metastatic Prostate Cancer.

Pritchard CC, Offit K, Nelson PS.

N Engl J Med. 2016 Nov 3;375(18):1804-5. doi: 10.1056/NEJMc1611137. No abstract available.

PMID:
27806229
34.

Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients.

Keel SB, Scott A, Sanchez-Bonilla M, Ho PA, Gulsuner S, Pritchard CC, Abkowitz JL, King MC, Walsh T, Shimamura A.

Haematologica. 2016 Nov;101(11):1343-1350. Epub 2016 Jul 14.

35.

Classification and characterization of microsatellite instability across 18 cancer types.

Hause RJ, Pritchard CC, Shendure J, Salipante SJ.

Nat Med. 2016 Nov;22(11):1342-1350. doi: 10.1038/nm.4191. Epub 2016 Oct 3. Erratum in: Nat Med. 2017 Oct 6;23 (10 ):1241. Nat Med. 2018 Apr 10;24(4):525.

PMID:
27694933
36.

DNA Repair in Prostate Cancer: Biology and Clinical Implications.

Mateo J, Boysen G, Barbieri CE, Bryant HE, Castro E, Nelson PS, Olmos D, Pritchard CC, Rubin MA, de Bono JS.

Eur Urol. 2017 Mar;71(3):417-425. doi: 10.1016/j.eururo.2016.08.037. Epub 2016 Aug 31. Review.

37.

Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.

Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B, True LD, Pritchard CC.

Oncotarget. 2016 Dec 13;7(50):82504-82510. doi: 10.18632/oncotarget.12697.

38.

Family-Specific Variants and the Limits of Human Genetics.

Shirts BH, Pritchard CC, Walsh T.

Trends Mol Med. 2016 Nov;22(11):925-934. doi: 10.1016/j.molmed.2016.09.007. Epub 2016 Oct 11. Review.

40.

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer.

Nghiem B, Zhang X, Lam HM, True LD, Coleman I, Higano CS, Nelson PS, Pritchard CC, Morrissey C.

Asian J Urol. 2016 Oct;3(4):223-228. doi: 10.1016/j.ajur.2016.09.002. Epub 2016 Sep 12.

41.

Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Roychowdhury S, Goswami S, Ippolito JE, Priceman SJ, Pritchard CC, Sfanos KS, Subudhi SK, Simons JW, Pienta KJ, Soule HR.

Prostate. 2017 Feb;77(2):123-144. doi: 10.1002/pros.23260. Epub 2016 Sep 28. Review.

PMID:
27679977
42.

PIK3CA-associated developmental disorders exhibit distinct classes of mutations with variable expression and tissue distribution.

Mirzaa G, Timms AE, Conti V, Boyle EA, Girisha KM, Martin B, Kircher M, Olds C, Juusola J, Collins S, Park K, Carter M, Glass I, Krägeloh-Mann I, Chitayat D, Parikh AS, Bradshaw R, Torti E, Braddock S, Burke L, Ghedia S, Stephan M, Stewart F, Prasad C, Napier M, Saitta S, Straussberg R, Gabbett M, O'Connor BC, Keegan CE, Yin LJ, Lai AH, Martin N, McKinnon M, Addor MC, Boccuto L, Schwartz CE, Lanoel A, Conway RL, Devriendt K, Tatton-Brown K, Pierpont ME, Painter M, Worgan L, Reggin J, Hennekam R, Tsuchiya K, Pritchard CC, Aracena M, Gripp KW, Cordisco M, Van Esch H, Garavelli L, Curry C, Goriely A, Kayserilli H, Shendure J, Graham J Jr, Guerrini R, Dobyns WB.

JCI Insight. 2016 Jun 16;1(9). pii: e87623.

43.

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.

Liu JF, Palakurthi S, Zeng Q, Zhou S, Ivanova E, Huang W, Zervantonakis IK, Selfors LM, Shen Y, Pritchard CC, Zheng M, Adleff V, Papp E, Piao H, Novak M, Fotheringham S, Wulf GM, English J, Kirschmeier PT, Velculescu VE, Paweletz C, Mills GB, Livingston DM, Brugge JS, Matulonis UA, Drapkin R.

Clin Cancer Res. 2017 Mar 1;23(5):1263-1273. doi: 10.1158/1078-0432.CCR-16-1237. Epub 2016 Aug 29.

44.

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, Chinnaiyan A, Vinson J, Filipenko J, Garraway L, Taplin ME, AlDubayan S, Han GC, Beightol M, Morrissey C, Nghiem B, Cheng HH, Montgomery B, Walsh T, Casadei S, Berger M, Zhang L, Zehir A, Vijai J, Scher HI, Sawyers C, Schultz N, Kantoff PW, Solit D, Robson M, Van Allen EM, Offit K, de Bono J, Nelson PS.

N Engl J Med. 2016 Aug 4;375(5):443-53. doi: 10.1056/NEJMoa1603144. Epub 2016 Jul 6.

45.

Circulating microRNAs and sudden cardiac arrest outcomes.

Wander PL, Enquobahrie DA, Pritchard CC, McKnight B, Rice K, Christiansen M, Lemaitre RN, Rea T, Siscovick D, Sotoodehnia N.

Resuscitation. 2016 Sep;106:96-101. doi: 10.1016/j.resuscitation.2016.06.038. Epub 2016 Jul 14.

46.

Tissue Is the Issue for Diagnosis of EGFR T790M Mutation.

Khan J, Pritchard CC, Martins RG.

J Thorac Oncol. 2016 Jul;11(7):e91-2. doi: 10.1016/j.jtho.2016.03.017. No abstract available.

47.

A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.

Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS, Pritchard CC.

Prostate. 2016 Oct;76(14):1303-11. doi: 10.1002/pros.23219. Epub 2016 Jun 21.

48.

Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.

Cohen SA, Turner EH, Beightol MB, Jacobson A, Gooley TA, Salipante SJ, Haraldsdottir S, Smith C, Scroggins S, Tait JF, Grady WM, Lin EH, Cohn DE, Goodfellow PJ, Arnold MW, de la Chapelle A, Pearlman R, Hampel H, Pritchard CC.

Gastroenterology. 2016 Sep;151(3):440-447.e1. doi: 10.1053/j.gastro.2016.06.004. Epub 2016 Jun 11.

49.

CADD score has limited clinical validity for the identification of pathogenic variants in noncoding regions in a hereditary cancer panel.

Mather CA, Mooney SD, Salipante SJ, Scroggins S, Wu D, Pritchard CC, Shirts BH.

Genet Med. 2016 Dec;18(12):1269-1275. doi: 10.1038/gim.2016.44. Epub 2016 May 5.

50.

Applying Ancestry and Sex Computation as a Quality Control Tool in Targeted Next-Generation Sequencing.

Mathias PC, Turner EH, Scroggins SM, Salipante SJ, Hoffman NG, Pritchard CC, Shirts BH.

Am J Clin Pathol. 2016 Mar;145(3):308-15. doi: 10.1093/ajcp/aqv098. Epub 2016 Feb 20.

PMID:
27124912

Supplemental Content

Loading ...
Support Center